Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4611356 | 0.90 | HSD17B10 (0.54) | CTSSHSD17B10ALDH1A1LMNAKDM4E | |
| SCHEMBL4611839 | 0.89 | DPP4 (0.41) | GRM5CTSSHSD17B10PKMLMNA | |
| SCHEMBL4611836 | 0.89 | DPP4 (0.41) | GRM5CTSSHSD17B10PKMLMNA | |
| SCHEMBL4609666 | 0.82 | CTSS (0.49) | CTSSHSD17B10PKMALDH1A1LMNA | |
| SCHEMBL4611829 | 0.81 | GAA (0.50) | LMNA | |
| SCHEMBL4610312 | 0.80 | HSD17B10 (0.43) | GRM5HSD17B10PKMRORCALDH1A1 | |
| SCHEMBL7156295 | 0.78 | HSD17B10 (0.50) | CTSSHSD17B10ALDH1A1LMNATP53 | |
| SCHEMBL4609351 | 0.78 | CTSS (0.41) | CTSSRORC | |
| SCHEMBL4612774 | 0.78 | LMNA (0.46) | CTSSHSD17B10RORCALDH1A1LMNA | |
| SCHEMBL4609903 | 0.77 | SMN1; SMN2 (0.38) | GRM5HSD17B10PKMLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641771-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | UCB PHARMA SA (BE) | 2008-10-15 | — | — | EP | disclosed |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD22, CD2, DPP3 | GRM5 1606/4885CTSS 81/4885HSD17B10 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.